Wong Craig S, Fink Christopher A, Baechle Jane, Harris Alexis A, Staples Amy O, Brandt John R
Department of Pediatrics, Division of Nephrology, University of New Mexico School of Medicine, MSC-10 5590, 1 University New Mexico, Albuquerque, NM 87131, USA.
Pediatr Nephrol. 2009 Apr;24(4):761-7. doi: 10.1007/s00467-008-1058-9. Epub 2008 Dec 11.
C1q nephropathy (C1qN) is an uncommon disorder seen in children and adults with nephrotic syndrome and non-specific urinary findings. It has been described with minimal change nephrotic syndrome (MCNS), focal segmental glomerulonephritis and isolated mesangial proliferative glomerulonephritis. We describe nine children with MCNS and mesangial C1q deposition. These children had a median age of 2.7 years at diagnosis (range 1.3-15 years), 56% were male and 78% were Hispanic. We compared these children to concurrent patients with nephrotic syndrome and biopsy-proven MCNS. We found that the C1qN patients were more likely than MCNS children to require chronic immunosuppression with calcineurin inhibitors or mycophenolate mofetil to maintain remission. However, all children were able to achieve and sustain clinical remission of nephrotic syndrome. Children with C1qN and minimal change histology have an increased frequency of frequently relapsing and steroid-unresponsive disease, but they can attain prolonged remission and stable renal function with calcineurin inhibitor or mycophenolate mofetil therapy.
C1q肾病(C1qN)是一种在患有肾病综合征和非特异性尿液检查结果的儿童及成人中少见的疾病。它曾被描述与微小病变肾病综合征(MCNS)、局灶节段性肾小球肾炎以及孤立性系膜增生性肾小球肾炎相关。我们描述了9例患有MCNS且系膜有C1q沉积的儿童。这些儿童诊断时的中位年龄为2.7岁(范围1.3 - 15岁),56%为男性,78%为西班牙裔。我们将这些儿童与同期患有肾病综合征且经活检证实为MCNS的患者进行了比较。我们发现,与MCNS儿童相比,C1qN患者更有可能需要使用钙调神经磷酸酶抑制剂或霉酚酸酯进行长期免疫抑制以维持缓解。然而,所有儿童都能够实现并维持肾病综合征的临床缓解。具有C1qN和微小病变组织学表现的儿童频繁复发和对类固醇无反应疾病的发生率增加,但通过钙调神经磷酸酶抑制剂或霉酚酸酯治疗,他们可以获得长期缓解和稳定的肾功能。